Atopic Dermatitis

A recent study indicated that lebrikizumab treatment for 16 weeks was effective for adolescents and adults with moderate-to-severe atopic dermatitis.

Results from a recent phase 3 clinical trial demonstrated topline safety and efficacy results for tapinarof cream, 1% (VTAMA; Dermavant) as a potential treatment for atopic dermatitis in patients 2 years and older.

A supplemental New Drug Application (sNDA) for abrocitinib (CIBINQO; Pfizer) in adolescents has been approved by the US Food and Drug Administration.

A recent study highlighted new information on racial disparities in health care for Black and Hispanic pediatric patients with atopic dermatitis.

Brittany Craiglow, MD, and Angela J Lamb, MD, discuss the varying presentation of atopic dermatitis (AD) among different skin types and skin color, as well as the challenges in gauging disease severity.

A recent article highlighted multiple therapies for treating atopic dermatitis, including many which do not require a prescription.

A recent article highlighted multiple forms of treatment for atopic dermatitis, detailing their benefits and adverse events.

Adults with atopic dermatitis saw improved symptoms when taking dupilumab compared to placebo, regardless of the age when they first presented with the condition.

Research suggested no significant relationship between peanut sensitivity and AD severity as measured by two scores, although the study was acknowledged to have a smaller population due to pandemic restrictions.

Recently announced data from the INTEGUMENT-1 phase 3 clinical trial demonstrated positive safety and efficacy results for atopic dermatitis patients 6 years and older treated with roflumilast cream (Arcutis Biotherapeutics).

New data presented at ACAAI 2022 observed various trends in allergies associated with eczema and eosinophilic esophagitis, comparing observed data with that of patients in the United States.

Dermavant Sciences recently announced positive results for VTAMA (tapinarof cream, 1%) for treatment of atopic dermatitis in children aged as young as 2 years.

New research suggests the sleep quality of caregivers and patients with atopic dermatitis (inadequately-controlled with topical therapies) may improve with dupilumab treatment.

A review examined the ways in which costs can be reduced for patients with varying types of atopic dermatitis.

In a recent article, researchers discussed current atopic dermatitis treatments, along with the need for safe and effective long-term treatments.

Improvements in atopic dermatitis symptoms were seen in children taking dupilumab, with minimal adverse events.

Joshua Zeichner, MD; Brittany Craiglow, MD; Elizabeth Swanson, MD; Vikash Oza, MD; and Raj Chovatiya, MD, PhD, provide take-home messages for dermatologists treating pediatric patients with atopic dermatitis.

Atopic dermatitis specialists discuss how to have a conversation with parents about risks of biologics and how to answer questions about length of therapy.

Expert pediatric dermatologists provide impressions on the case of a 12-year-old girl with atopic dermatitis.

Joshua Zeichner, MD, reviews the case of a 12-year-old girl with atopic dermatitis.

Joshua Zeichner, MD; Brittany Craiglow, MD; Elizabeth Swanson, MD; and Vikash Oza, MD, address techniques for injectables when treating pediatric patients with atopic dermatitis.

Expert pediatric dermatologists discuss the importance of combination therapy and shared decision-making when treating pediatric patients with atopic dermatitis.

Brittany Craiglow, MD, and Joshua Zeichner, MD, discuss treatment adherence in pediatric patients with atopic dermatitis.

Vikash Oza, MD, provides clinical insight for Case 2, a 7-year-old female patient with atopic dermatitis.

Dr Joshua Zeichner reviews the case of a 7-year-old female patient with atopic dermatitis.

Joshua Zeichner, MD; Brittany Craiglow, MD; Elizabeth Swanson, MD; Vikash Oza, MD; and Raj Chovatiya, MD, PhD, discuss treatments beyond topical agents and the use of dupilumab in pediatric patients with atopic dermatitis.

Expert pediatric dermatologists Drs Elizabeth Swanson, Joshua Zeichner, and Raj Chovatiya share impressions from patient case No. 1.

Dr Joshua Zeichner reviews the case of a 2-year-old patient with atopic dermatitis.

Taylor Capps and her mother, Tina Capps, share Taylor’s initial journey with atopic dermatitis and presenting symptoms.

Children with atopic dermatitis will soon have more options for treatment, as clinical trials show promising results.